株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界の組織工学(ティッシュエンジニアリング)市場:市場規模、シェア、動向分析 - 応用分野(臍帯血・細胞バンク、癌、婦人科、歯科、皮膚科、整形外科)、地域別 2012年~2022年

Tissue Engineering Market Size, Share & Trends Analysis Report By Application (Cord Blood & Cell Banking, Cancer, GI & Gynecology, Dental, Skin/Integumentary, Orthopedics), And Segment Forecasts, 2012 - 2022

発行 Grand View Research, Inc. 商品コード 639944
出版日 ページ情報 英文 93 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=109.53円で換算しております。
Back to Top
世界の組織工学(ティッシュエンジニアリング)市場:市場規模、シェア、動向分析 - 応用分野(臍帯血・細胞バンク、癌、婦人科、歯科、皮膚科、整形外科)、地域別 2012年~2022年 Tissue Engineering Market Size, Share & Trends Analysis Report By Application (Cord Blood & Cell Banking, Cancer, GI & Gynecology, Dental, Skin/Integumentary, Orthopedics), And Segment Forecasts, 2012 - 2022
出版日: 2018年04月03日 ページ情報: 英文 93 Pages
概要

世界の組織工学(ティッシュエンジニアリング)市場は、2022年までに115億米ドル規模の市場に成長することが予測されています。慢性疾患、交通事故、外傷による病変や損傷などの増加が組織工学ソリューションの成長に寄与しています。

当レポートでは、世界の組織工学(ティッシュエンジニアリング)市場を調査し、市場の概要、応用分野・地域別の市場動向、市場規模の推移と予測、市場シェア、成長要因・阻害要因ならびに市場機会の分析、競合情勢、主要企業のプロファイルなど、体系的な情報を提供しています。

目次

第1章 調査方法と範囲

  • 調査方法
  • 調査範囲と前提条件
  • 情報源のリスト

第2章 エグゼクティブサマリー

第3章 産業概要

  • 市場区分
  • 市場規模と成長率の見通し
  • 市場のダイナミクス
    • 成長要因の分析
    • 阻害要因の分析
  • 需要な市場機会
  • ファイブフォース分析
  • PESTEL分析

第4章 世界の組織工学(ティッシュエンジニアリング)市場:応用分野別

  • 市場シェア:応用分野別(実績値・予測値)
  • 臍帯血・細胞バンク
  • 癌・腫瘍科
  • 婦人科
  • 歯科
  • 皮膚科
  • 泌尿器科
  • 整形外科
  • 神経科
  • 循環器科

第5章 世界の組織工学(ティッシュエンジニアリング)市場:地域別

  • 北米
  • 欧州
  • アジア太平洋地域
  • ラテンアメリカ
  • 中東・アフリカ

第6章 競合情勢

  • Medtronic Inc.
  • Zimmer Biomet
  • Acelity
  • Acell Inc
  • Athersys Inc
  • Organogenesis Inc
  • Stryker Corporation
  • Tissue Regenix Group Plc
  • RTI Surgical Inc.
  • ReproCell Inc.
図表

List of Tables

  • 1. Tissue engineering market - Industry summary & key buying criteria, 2012 - 2022
  • 2. Tissue engineering market, by application, 2012 - 2022 (USD million)
  • 3. Tissue engineering market, by region, 2012 - 2022 (USD million)
  • 4. Tissue engineering market - Key market driver's analysis
  • 5. Tissue engineering market - Key market restraints analysis
  • 6. North America market, by application, 2012 - 2022 (USD million)
  • 7. U.S market, by application, 2012 - 2022 (USD million)
  • 8. Canada market, by application, 2012 - 2022 (USD million)
  • 9. Europe market, by application, 2012 - 2022 (USD million)
  • 10. UK market, by application, 2012 - 2022 (USD million)
  • 11. France market, by application, 2012 - 2022 (USD million)
  • 12. Germany market, by application, 2012 - 2022 (USD million)
  • 13. Asia Pacific market, by application, 2012 - 2022 (USD million)
  • 14. Japan market, by application, 2012 - 2022 (USD million)
  • 15. China market, by application, 2012 - 2022 (USD million)
  • 16. India market, by application, 2012 - 2022 (USD million)
  • 17. Latin America market, by application, 2012 - 2022 (USD million)
  • 18. Mexico market, by application, 2012 - 2022 (USD million)
  • 19. Brazil market, by application, 2012 - 2022 (USD million)
  • 20. Middle East and Africa (MEA) market, by application, 2012 - 2022 (USD million)
  • 21. South Africa market, by application, 2012 - 2022 (USD million)

List of Figures

  • 1. Tissue engineering segmentation
  • 2. Global tissue engineering revenue, 2012 - 2022
  • 3. Tissue engineering dynamics
  • 4. Key opportunities prioritized
  • 5. Tissue engineering analysis - Porter's
  • 6. Tissue engineering analysis - PESTEL analysis
  • 7. Global tissue engineering, by application, 2012 - 2022 (USD million)
  • 8. Cord blood & cell banking market, 2012 - 2022 (USD million)
  • 9. Cancer market, 2012 - 2022 (USD million)
  • 10. GI & gynecology market, 2012 - 2022 (USD million)
  • 11. Dental market, 2012 - 2022 (USD million)
  • 12. Skin/integumentary market, 2012 - 2022 (USD million)
  • 13. Urology market, 2012 - 2022 (USD million)
  • 14. Orthopedics, musculoskeletal and spine market, 2012 - 2022 (USD million)
  • 15. Neurology market, 2012 - 2022 (USD million)
  • 16. Cardiology & vascular market, 2012 - 2022 (USD million)
  • 17. Global tissue engineering market, by region 2012 to 2022 (USD million)
  • 18. North America tissue engineering market, by application, 2012 to 2022 (USD million)
  • 19. U.S. tissue engineering market, by application, 2012 to 2022 (USD million)
  • 20. Canada tissue engineering Market, by application, 2012 to 2022 (USD million)
  • 21. Europe tissue engineering market, by application, 2012 to 2022 (USD million)
  • 22. UK tissue engineering market, by application, 2012 to 2022 (USD million)
  • 23. France tissue engineering market, by application, 2012 to 2022 (USD million)
  • 24. Germany tissue engineering market, by application, 2012 to 2022 (USD million)
  • 25. Asia Pacific tissue engineering market, by application, 2012 to 2022 (USD million)
  • 26. Japan tissue engineering market, by application, 2012 to 2022 (USD million)
  • 27. China tissue engineering market, by application, 2012 to 2022 (USD million)
  • 28. India tissue engineering market, by application, 2012 to 2022 (USD million)
  • 29. Latin America tissue engineering market, by application, 2012 to 2022 (USD Million)
  • 30. Brazil tissue engineering market, by application, 2012 to 2022 (USD million)
  • 31. Mexico tissue engineering market, by application, 2012 to 2022 (USD million)
  • 32. MEA tissue engineering market, by application, 2012 to 2022 (USD million)
  • 33. South Africa tissue engineering market, by application, 2012 to 2022 (USD million)
目次
Product Code: 978-1-68038-768-1

The global tissue engineering market is expected to reach USD 11.5 billion by 2022, according to a new report by Grand View Research, Inc. According to the U.S. Centers of Medicare and Medicaid, more than 900 million surgeries are performed for bone reconstruction or replacement. Increasing cases of chronic diseases, road accidents, and trauma injuries is contributing to the growth in development of tissue engineering solutions. In addition, the funding by government for the ongoing research for tissue regeneration is a major driver for market growth.

Currently used tissue repair solutions include surgeries, medical devices, and transplants. Tissue engineering procedures have a huge potential to replace the conventional tissue repair options. The technological advancements in 3D tissue engineering, including use of 3D bio-printers to design in-vitro implants and replacement of embryo cells with proliferative stem cells are likely to boost the market growth in the years to come.

Further Key Findings From The Report Suggest:

Orthopedics, Musculoskeletal, and Spine segment held majority of the application revenue in the year 2014, due to research funding and new product developments.

Geistlich Pharma launched bone-harvesting instruments in 2016, for the collection of autogenous bones. This product restores bone volume and properties.

Cardiology and vascular segment is likely to grow at the fastest rate in the coming years, pertaining to rapidly rising incidence rate of cardiovascular diseases due to lifestyle changes.

The focus on cardiovascular tissue engineering solutions is expected to increase as cardiovascular disorders is one of the major causes of death across the globe.

North America held majority of revenue share, due to presence of major market players in the region, huge R&D funding, and growing base of geriatric population.

Zimmer Biomet acquired Ortho Transmission for its pioneered technology, which could restore limb amputee patients. With this acquisition, Zimmer can efficiently work on its current project received by the department of defense, U.S.

Asia Pacific is likely to showcase the fastest growth rate in the coming years, owing to the foreign direct investments in this region.

In 2013, Japanese Ministry of Healthcare approved clinical trial for developing induced pluriponent stem (iPS) cells for blindness.

Stryker Corporation, Medtronic, Inc., Organogenesis, Inc., Zimmer Biomet, Acelity, Athersys, Inc., Tissue Regenix Group Plc and RTI surgical, Inc. are some of the key players operating in this market.

New product developments, mergers and acquisitions are some of the strategies undertaken by these companies to strengthen their market presence.

ReproCell, Inc. acquired Biopta in 2015 to gain advantage on Bipota's clinical network in the U.S and the UK.

Table of Content

Chapter 1. Methodology and Scope

  • 1.1. Research methodology
  • 1.2. Research scope & assumption
  • 1.3. List of data sources

Chapter 2. Executive Summary

  • 2.1. Tissue engineering - Industry summary and key buying criteria, 2012 - 2022

Chapter 3. Tissue Engineering Industry Outlook

  • 3.1. Tissue engineering segmentation
  • 3.2. Tissue engineering size and growth prospects
  • 3.3. Tissue engineering dynamics
    • 3.3.1. Market driver analysis
    • 3.3.2. Market restraint analysis
  • 3.4. Key opportunities prioritized
  • 3.5. Industry analysis - Porter's
  • 3.6. Tissue engineering PESTEL analysis, 2014

Chapter 4. Tissue Engineering Application Outlook

  • 4.1. Tissue engineering share by application, 2014 & 2022
  • 4.2. Cord blood & cell banking market estimates and forecasts, 2012 - 2022 (USD million)
  • 4.3. Cancer market estimates and forecasts, 2012 - 2022 (USD million)
  • 4.4. GI & gynecology market estimates and forecasts, 2012 - 2022 (USD million)
  • 4.5. Dental market estimates and forecasts, 2012 - 2022 (USD million)
  • 4.6. Skin/integumentary market estimates and forecasts, 2012 - 2022 (USD million)
  • 4.7. Urology market estimates and forecasts, 2012 - 2022 (USD million)
  • 4.8. Orthopedics, musculoskeletal and spine market estimates and forecasts, 2012 - 2022 (USD million)
  • 4.9. Neurology market estimates and forecasts, 2012 - 2022 (USD million)
  • 4.10. Cardiology & vascular market estimates and forecasts, 2012 - 2022 (USD million)

Chapter 5. Tissue Engineering Regional Outlook

  • 5.1. North America
    • 5.1.1. tissue engineering market estimates and forecasts, by application, 2012 - 2022 (USD million)
      • 5.1.1.1. U.S market estimates and forecasts, 2012 - 2022 (USD million)
      • 5.1.1.2. Canada market estimates and forecasts, 2012 - 2022 (USD million)
  • 5.2. Europe
    • 5.2.1. tissue engineering market estimates and forecasts, by application, 2012 - 2022 (USD million)
      • 5.2.1.1. UK market estimates and forecasts, 2012 - 2022 (USD million)
      • 5.2.1.2. France market estimates and forecasts, 2012 - 2022 (USD million)
      • 5.2.1.3. Germany market estimates and forecasts, 2012 - 2022 (USD million)
  • 5.3. Asia Pacific
    • 5.3.1. tissue engineering market estimates and forecasts, by application, 2012 - 2022 (USD million)
      • 5.3.1.1. India market estimates and forecasts, 2012 - 2022 (USD million)
      • 5.3.1.2. China market estimates and forecasts, 2012 - 2022 (USD million)
      • 5.3.1.3. Japan market estimates and forecasts, 2012 - 2022 (USD million)
  • 5.4. Latin America
    • 5.4.1. tissue engineering market estimates and forecasts, by application, 2012 - 2022 (USD Million)
      • 5.4.1.1. Mexico market estimates and forecasts, 2012 - 2022 (USD Million)
      • 5.4.1.2. Brazil market estimates and forecasts, 2012 - 2022 (USD Million)
  • 5.5. MEA
    • 5.5.1. tissue engineering market estimates and forecasts, by application, 2012 - 2022 (USD million)
      • 5.5.1.1. South Africa market estimates and forecasts, 2012 - 2022 (USD million)

Chapter 6. Competitive Landscape

  • 6.1. Medtronic Inc.
    • 6.1.1. Company Overview
    • 6.1.2. Financial Performance
    • 6.1.3. Procedures Benchmarking
    • 6.1.4. Strategic Initiatives
  • 6.2. Zimmer Biomet
    • 6.2.1. Company Overview
    • 6.2.2. Financial Performance
    • 6.2.3. Procedures Benchmarking
    • 6.2.4. Strategic Initiatives
  • 6.3. Acelity
    • 6.3.1. Company Overview
    • 6.3.2. Financial Performance
    • 6.3.3. Procedures Benchmarking
    • 6.3.4. Strategic Initiatives
  • 6.4. Acell Inc
    • 6.4.1. Company Overview
    • 6.4.2. Financial Performance
    • 6.4.3. Procedures Benchmarking
    • 6.4.4. Strategic Initiatives
  • 6.5. Athersys Inc
    • 6.5.1. Company Overview
    • 6.5.2. Financial Performance
    • 6.5.3. Procedures Benchmarking
    • 6.5.4. Strategic Initiatives
  • 6.6. Organogenesis Inc
    • 6.6.1. Company Overview
    • 6.6.2. Financial Performance
    • 6.6.3. Procedures Benchmarking
    • 6.6.4. Strategic Initiatives
  • 6.7. Stryker Corporation
    • 6.7.1. Company Overview
    • 6.7.2. Financial Performance
    • 6.7.3. Procedures Benchmarking
    • 6.7.4. Strategic Initiatives
  • 6.8. Tissue Regenix Group Plc
    • 6.8.1. Company Overview
    • 6.8.2. Financial Performance
    • 6.8.3. Procedures Benchmarking
    • 6.8.4. Strategic Initiatives
  • 6.9. RTI Surgical Inc.
    • 6.9.1. Company Overview
    • 6.9.2. Financial Performance
    • 6.9.3. Procedures Benchmarking
    • 6.9.4. Strategic Initiatives
  • 6.10. ReproCell Inc.
    • 6.10.1. Company Overview
    • 6.10.2. Financial Performance
    • 6.10.3. Procedures Benchmarking
    • 6.10.4. Strategic Initiatives
Back to Top